Effects of NMDA receptor antagonists: implications for the pathophysiology of schizophrenia.
暂无分享,去创建一个
[1] D. Schoepp,et al. Regulation of Neurotransmitter Release by Metabotropic Glutamate Receptors , 2000, Journal of neurochemistry.
[2] G. Aghajanian,et al. Serotonin model of schizophrenia: emerging role of glutamate mechanisms , 2000, Brain Research Reviews.
[3] M. Laruelle,et al. Increased dopamine transmission in schizophrenia: relationship to illness phases , 1999, Biological Psychiatry.
[4] B. Moghaddam,et al. Reversal of phencyclidine effects by a group II metabotropic glutamate receptor agonist in rats. , 1998, Science.
[5] Takeshi Kawahara,et al. Involvement of γ-aminobutyric acid neurotransmission in phencyclidine-induced dopamine release in the medial prefrontal cortex , 1998 .
[6] Bita Moghaddam,et al. Activation of Glutamatergic Neurotransmission by Ketamine: A Novel Step in the Pathway from NMDA Receptor Blockade to Dopaminergic and Cognitive Disruptions Associated with the Prefrontal Cortex , 1997, The Journal of Neuroscience.
[7] M. Hasselmo,et al. NMDA-dependent modulation of CA1 local circuit inhibition , 1996, The Journal of neuroscience : the official journal of the Society for Neuroscience.
[8] J. Olney,et al. NMDA Antagonists as Neurotherapeutic Drugs, Psychotogens, Neurotoxins, and Research Tools for Studying Schizophrenia , 1995, Neuropsychopharmacology.
[9] B. Meldrum. The role of glutamate in epilepsy and other CNS disorders , 1994, Neurology.
[10] A. Belger,et al. NMDA agonists and antagonists as probes of glutamatergic dysfunction and pharmacotherapies in neuropsychiatric disorders. , 1999, Harvard review of psychiatry.
[11] D. Javitt,et al. Efficacy of high-dose glycine in the treatment of enduring negative symptoms of schizophrenia. , 1999, Archives of general psychiatry.